LACTOLOGY FOUNDATION

Peripheral opioid receptor antagonists (ATC class A06AH) are used to treat opioid‑induced constipation while preserving central analgesia and require careful lactation‑specific risk assessment for each individual agent.atcddd.fhi+1

Pharmacotherapeutic group and mechanisms

A06AH comprises peripherally acting opioid receptor antagonists (PAMORAs) indicated for constipation caused by opioid analgesics, classified within “Drugs for constipation” in the alimentary tract and metabolism ATC group A.atcddd.fhi+1
These agents selectively antagonize µ‑opioid receptors in the gastrointestinal tract, thereby restoring gut motility and secretion without crossing the blood–brain barrier at therapeutic doses and without significantly affecting central analgesia. Peripheral selectivity is achieved through limited oral bioavailability, polar or charged structures, and/or use of substrates for efflux transporters, which reduces central nervous system penetration.

Active substances within A06AH

According to the WHO ATC/DDD Index, the class currently contains five substances: methylnaltrexone bromide (A06AH01), alvimopan (A06AH02), naloxegol (A06AH03), naloxone (A06AH04) and naldemedine (A06AH05).atcddd.fhi
Defined daily doses (DDD) are established for methylnaltrexone bromide (6 mg parenteral), naloxegol (25 mg oral) and naldemedine (0.2 mg oral), while DDDs for alvimopan and naloxone in this ATC context are not specified in the index table.atcddd.fhi

General toxicological profile

PAMORAs are designed to act locally in the gut, but systemic exposure occurs for most agents and determines their non‑gastrointestinal toxicity profile. Class‑related adverse effects include abdominal pain, diarrhea, nausea, vomiting and flatulence; in patients with conditions predisposing to intestinal obstruction or perforation, serious gastrointestinal events have been reported for some agents in post‑marketing surveillance. Because they reverse peripheral opioid effects, they may precipitate symptoms of opioid withdrawal in susceptible individuals, especially with high opioid doses or in patients with compromised blood–brain barrier. Standard toxicological concerns include the potential for cardiovascular events (reported for individual drugs such as alvimopan in specific indications), hepatic or renal impairment requiring dose consideration, and drug–drug interactions mediated by transporters and cytochrome P450 enzymes (notably CYP3A for naloxegol and naldemedine). Preclinical reproductive toxicology data generally do not indicate major teratogenic risk, but human pregnancy and lactation data remain limited, and standard precautionary principles apply.

Lactation‑toxicology considerations

Human data on the use of A06AH agents during breastfeeding are scarce, and none of the substances is widely characterized as clearly compatible with lactation in major guidelines.atcddd.fhi
Theoretical lactation risk is driven by: (1) physicochemical properties (molecular weight, polarity, protein binding) affecting transfer into breast milk; (2) oral bioavailability of any drug ingested by the infant; and (3) potential to antagonize opioid receptors in the infant gut or systemically, with possible interference in analgesia or withdrawal phenomena when the mother or infant receives opioids.

For methylnaltrexone bromide (A06AH01), the quaternary ammonium structure and poor oral bioavailability suggest low milk transfer and limited infant exposure; however, the absence of robust clinical series in breastfeeding women supports a cautious, case‑by‑case approach. Naloxegol (A06AH03) and naldemedine (A06AH05) are orally active small molecules, and if present in breast milk, they could be absorbed by the infant and potentially antagonize opioid receptors in the gut; data are insufficient to quantify this risk. Alvimopan (A06AH02) has restricted indications and limited duration of use; systemic exposure is present, but no targeted lactation studies have been published. Naloxone (A06AH04) has long clinical experience as an opioid antagonist in other ATC classes; it has short half‑life, and small amounts in breast milk would likely be rapidly cleared, yet its ability to precipitate withdrawal in exposed individuals requires caution, especially when the breastfeeding dyad is on opioid therapy.

In the absence of high‑quality human lactation data, most reference sources consider the entire class as lacking evidence for routine use in breastfeeding, recommending alternative strategies for constipation in nursing mothers whenever possible. When PAMORAs are clinically necessary (e.g. refractory opioid‑induced constipation in a postpartum woman on high‑dose opioids), an individualized risk–benefit assessment is advised, including: limiting treatment duration; using the lowest effective dose; timing dosing just after breastfeeding; and monitoring the infant for changes in feeding, stool pattern, irritability or signs of opioid withdrawal. Consultation with a specialist in clinical pharmacology, toxicology or lactation medicine is recommended.

Clinical use in breastfeeding women

Opioid‑induced constipation is common in peripartum and postoperative patients, but breastfeeding women are usually managed with non‑pharmacological measures and conventional laxatives (osmotic or bulk‑forming agents) with better characterized safety profiles in lactation.atcddd.fhi
A06AH agents should generally be reserved for situations in which standard laxatives are ineffective or contraindicated, and the maternal need to continue opioid analgesia is compelling. In these scenarios, methylnaltrexone bromide or naloxegol are more frequently considered because of their established roles in opioid‑induced constipation; however, their use in breastfeeding remains off‑label with limited supporting evidence, and shared decision‑making is essential. Documentation of maternal indication, dosing, duration and infant monitoring should be part of the clinical record in any lactation exposure.